Agios Pharmaceuticals, Inc. (AGIO)
26.82
-0.64
(-2.33%)
USD |
NASDAQ |
Dec 12, 13:12
Agios Pharmaceuticals Cash from Investing (Quarterly): 95.56M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Pfizer Inc. | -2.43B |
| Fulcrum Therapeutics, Inc. | 18.61M |
| Moderna, Inc. | 700.00M |
| EyePoint Plc | 55.38M |
| Vanda Pharmaceuticals, Inc. | 21.36M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -88.15M |
| Cash from Financing (Quarterly) | 4.435M |
| Free Cash Flow | -414.09M |
| Free Cash Flow Per Share (Quarterly) | -1.543 |
| Free Cash Flow to Equity (Quarterly) | -85.46M |
| Free Cash Flow to Firm (Quarterly) | -89.71M |
| Free Cash Flow Yield | -26.77% |